Air Partner
REDUCEShareholder returns at Air Partner, the world’s largest aircraft charter broker, continue to soar.
Record results for the year to July revealed a 49% profits rise to £7.6m, on sales up more than 30% at £185.8m, with client numbers increasing by 38%. Cash balances increased from £11.9m to £19.5m, despite Air Partner, whose clients range from heads of state to corporate customers and celebrities, using £5.1m to fund last year’s Gold Air acquisition.
From earnings increased to 50.3p (34.4p), Air Partner proposes both a 13.3p final dividend – a 13th consecutive 10% increase – as well as a 60p special payout equating to £6m.
The group’s recent successes reflect a focus on the core corporate and government business, expansion into the private high-net-worth market, diversification in terms of ‘product, geography and clients’, high levels of client service and ‘a back drop of near-perfect trading conditions’, said chief executive David Savile.
Investors yet to book some profits – GCI was an early backer of Air Partner at 435p – should do so now, since the shares trade on a historic price to earnings ratio of 26 times. Having said that, stay meaningfully exposed, with Air Partner throwing off cash and dividends and thriving in an industry enjoying stellar growth, as wealthier travellers fall out of love with the scheduled airline experience. Reduce.
Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations. To subscribe today, and gain immediate access, click here
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £130m
Share price: 1310p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
